Moderna, Inc. (NASDAQ:MRNA) has seen a 38% loss in 2025 due to slipping demand for its mRNA vaccines. Revenue guidance was lowered to $1.5-2.2 billion due to deferred revenue from COVID vaccines. Jim Cramer discussed the stock, noting the challenges it faces in the current market.

Jim Cramer discussed Moderna, Inc. (NASDAQ:MRNA) in May, acknowledging its potential value but expressing caution. He mentioned the stock’s history and suggested a price target of $18. Cramer sees potential in Moderna but remains cautious.

While Moderna, Inc. (MRNA) has investment potential, some AI stocks may offer higher returns with less downside risk. For those seeking AI stocks with promising growth potential, a report on the best short-term AI stock is available. Consider diversifying your portfolio with these options for better returns.

Read more at Yahoo Finance: Moderna, Inc. (MRNA)’s “Got The Double Whammy,” Says Jim Cramer